NovoCure Limited (NVCR)

$79.52

+4.62 (+6.17%)
Rating:
Recommendation:
Neutral
Symbol NVCR
Price $79.52
Beta 0.806
Volume Avg. 0.71M
Market Cap 8.446B
Shares () -
52 Week Range 56.055-120.03
1y Target Est -
DCF Unlevered NVCR DCF ->
DCF Levered NVCR LDCF ->
ROE -20.98% Sell
ROA -7.77% Neutral
Operating Margin -
Debt / Equity 170.11% Buy
P/E -56.80 Strong Sell
P/B 18.93 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NVCR news


Mr. Asaf Danziger
Healthcare
Medical Instruments & Supplies
NASDAQ Global Select

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.